How spinal cord stimulation works
Interrupting pain signals before they reach the brain
Spinal cord stimulation uses a small implantable device to deliver tiny electrical pulses to the spinal cord. These pulses interrupt pain signals before they reach the brain, reducing the sensation of pain.
One advantage of SCS therapy is that it can be tried for a short period before a decision is made about a long-term implant.
A conversation with your specialist
Your care team will review previous treatments, the location and type of pain, health history, and whether a trial is appropriate.
What makes Evoke different?
Feedback from the spinal cord
The approved module explains how the system listens, personalizes, adapts, and responds in real time.
Saluda-approved patient education
Pain relief that adapts to you
Explore the official Evoke SmartSCS website module supplied by Saluda Medical.
Now offering Evoke Website module by Sydney Wess
Now offering Evoke Website by Sydney Wess
Questions to discuss
Preparing for an SCS conversation
A treatment page should help patients ask informed questions without presenting SCS as appropriate for everyone.
Approved patient education
Learn more
Keep manufacturer materials intact and link directly when a local approved copy is unavailable.
Important safety and regulatory information
U.S. Indications for Use: The Saluda Medical Evoke® SCS System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain, and diabetic peripheral neuropathy of the lower extremities.
Contraindications: The Evoke System must not be used in patients who do not receive effective pain relief during trial stimulation, are unable to operate the system, or are unsuitable surgical candidates.
Warnings: Sources of electromagnetic interference—including diathermy, MRI, CT scans, electrosurgery, lithotripsy, external defibrillation, radiation therapy, ultrasonic scanning, high-output ultrasound, TENS, psychotherapeutic procedures, and laser procedures—can interact with the system, resulting in unexpected stimulation changes, serious injury, or death. An implanted cardiac device may interact with a neurostimulator. Allergic reaction to system components may occur. The system has not been tested in patients who are pregnant or nursing or under age 18. Surgical complications and adverse events may be more frequent and severe in diabetic patients. PCLC stimulation and frequencies above 1200 Hz have not been evaluated for effectiveness in the DPN population.
Precautions: Patients should avoid manipulating the system through the skin. Therapy should be discontinued immediately if any component malfunctions or fails. Surgical complication severity may be greater in diabetic patients, particularly with inadequate pre-operative glycemic control.
Potential risks: Risks may include epidural abscess, wound infection, lead breakage or fracture, lead migration, IPG pocket pain, and muscle spasm or cramp. Rx Only.
Permissions and publication note
The Saluda 2026 Media Kit permits use for promotional and educational websites but prohibits editing, modification, alteration, transformation, or derivative works. Images may be used only in Saluda-branded materials. Retain the media kit permission page. Regulatory authorities require complete and balanced benefit and risk information consistent with FDA labeling. The exact website module and this disclosure should receive Saluda Regulatory or Medical Affairs review before publication.
Saluda and Evoke are registered trademarks of Saluda Medical Pty Limited. Copyright © 2026 Saluda Medical Pty Ltd. D106515.
